About OptraSCAN
OptraSCAN is a pioneering digital pathology company dedicated to transforming pathology services through advanced digital slide scanners and AI-driven solutions. The company holds various patents on automatic scanning device technology coupled with tumor and immune cell intelligent scoring systems. OptraSCAN empowers healthcare institutions to transition from traditional microscopes to digital pathology for improved diagnostics, research, and education. The company's comprehensive product portfolio includes multiple whole slide scanner models (OS-Ultra, OS-SiX, OS-Lite, OS-FLi for fluorescence), the IMAGEPath image management system, and AI-powered analytics solutions. Their integrated solutions target specific clinical applications including tuberculosis monitoring (BactoSiA), cervical cancer screening (CytoSiA), and breast cancer analysis (HistoSiA). OptraSCAN's technology offers high-speed precise imaging and analysis that streamlines laboratory workflows, enhancing diagnostic accuracy and improving patient outcomes. The company provides flexible deployment models including traditional capital equipment purchases and innovative on-demand solutions such as pay-per-use scanning, telepathology services, and digital lab-as-a-service offerings. Their IMAGEPath platform enables secure storage, viewing, sharing, and collaboration on whole slide images with HIPAA-compliant cloud or local server options. OptraSCAN serves pathology laboratories, hospitals, research centers, and healthcare institutions globally, supporting both clinical diagnostics and research applications across multiple disease areas including oncology, infectious diseases, and cytology.
Mission & Story
Mission
Dedicated to transforming the future of pathology services through advanced digital slide scanners and AI-driven solutions
Clinical Focus
Medical conditions and clinical areas addressed by OptraSCAN.
Who It Serves
Milestones & Awards
Recent Milestones
Launch of BactoSiA for TB monitoring and follow-up, Launch of HistoSiA Breast pay-per-use solution, Launch of OS-FS Frozen Section imaging modality, Exhibiting at 115th USCAP Annual Meeting, Attending 12th Digital Pathology and AI Congress Europe (London, Dec 2025), Attending World Health Expo
Awards & Recognition
Company mentions awards section but specific awards not detailed in scraped content
Key Partnerships
Social & Media
Latest Updates
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.